Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus HUMALOG PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 versus HUMALOG PEN.
HUMALOG MIX 75/25 vs HUMALOG PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphasic insulin analog combining rapid-acting insulin lispro (25%) and intermediate-acting insulin lispro protamine suspension (75%). Insulin lispro lowers blood glucose by binding to insulin receptors, facilitating cellular glucose uptake, inhibiting hepatic gluconeogenesis, and promoting glycogenesis and lipogenesis.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways (e.g., PI3K/Akt) to promote glucose uptake in skeletal muscle and adipose tissue, inhibit hepatic gluconeogenesis, and regulate lipid and protein metabolism.
Subcutaneous injection: 75% insulin lispro protamine suspension and 25% insulin lispro solution. Dose individualized based on glycemic goals and prior insulin regimen. Typical total daily dose: 0.5-1 unit/kg/day divided into two doses (pre-breakfast and pre-dinner).
Subcutaneously 0.5–1 unit/kg/day divided into multiple doses (usually 3 or more), administered 15 minutes before or immediately after meals.
None Documented
None Documented
Insulin lispro: 0.5-1 hour; protamine-bound fraction prolongs absorption, resulting in a biphasic profile with an effective half-life of 2-4 hours for the 75% NPL component.
Approximately 0.5-1 hour (rapid; subcutaneous absorption rate-limited).
Renal: 60-80% as unchanged drug following subcutaneous absorption; the remaining fraction undergoes hepatic metabolism and biliary/fecal excretion.
Renal: 60-80% of dose excreted as metabolites; remainder hepatobiliary and fecal.
Category C
Category C
Insulin Analog
Insulin Analog